1. Pink Sheet
  2. >>Market Access
  3. >>Government Payers
  4. >>Medicare

CMS Input On Pivotal Trials Could Anticipate Medicare Coverage Issues – Brooks-LaSure

 
• By Cathy Kelly

Centers for Medicare and Medicaid Services Administrator Chiquita Brooks-LaSure responds to US Congressional concerns about the proposed Medicare coverage policy for Alzheimer’s drugs.

CMS tries to educate Congress on Medicare coverage policy as its final Alzheimer's drug decision approaches. • Source: Alamy

US Centers for Medicare and Medicaid Services Administrator Chiquita Brooks-LaSure pitched early agency engagement with drug developers as a way to forestall possible Medicare coverage restrictions in an 18 March letter to Republican members of Congress.

She was responding to letters sent to her and Health and Human Services Secretary Xavier Becerra urging reversal of the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Medicare

More from Government Payers

US Budget Bill Eases IRA Price Controls But Coverage Losses Will Impact Pharma

 
• By Cathy Kelly

The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.

How Could MFN Pricing Impact Commercial Market?

 
• By Angela Maas

Industry experts forecast the impact of President Trump's Most-Favored Nation drug pricing policy on the commercial insurance industry.

Medicare’s Combo Products Negotiation Plan Conflicts With US FDA Standards, Firms Argue

 
• By Cathy Kelly

The plan could curtail a period of pricing flexibility for newer subcutaneous versions of important oncology drugs.